🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Encaleret

    BridgeBio Oncology Therapeutics

    Autosomal Dominant Hypocalcemia (ADH)

    phase 3 small molecule active

    2 trials

  2. Encaleret

    BridgeBio Oncology Therapeutics

    Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    phase 3 small molecule active

    1 trial

  3. Endoscopic submucosal dissection

    United Therapeutics Europe Ltd

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  4. Endostar

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  5. Endoxifen, Identical placebo tablets of Endoxifen manufactured by Intas Pharmaceuticals Limited, India. The placebo tablets were manufactured using the same excipients and the manufacturing process of endoxifen tablets. Like endoxifen 8 mg tablets, the placebo tablets are green coloured, round shape, biconvex, enteric coated tablets plain on both sides. The placebo for Endoxifen Tablets 8 mg was manufactured following the same procedure as the drug product without using endoxifen citrate.

    Lacuna Pharma Pty Ltd

    Bipolar I Disorder

    phase 3 small molecule active

    1 trial

  6. Enhanced standard management

    United Therapeutics Europe Ltd

    Pacemaker Complication

    phase 3 other active

    1 trial

  7. Epetraborole

    AN2 Therapeutics

    MAC Lung Disease

    phase 3 small molecule terminated

    1 trial

  8. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  9. Erenumab

    United Therapeutics Europe Ltd

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  10. Eribulin Mesylate

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 3 small molecule on hold

    1 trial

  11. Ertapenem

    Iterum Therapeutics plc

    Intra Abdominal Infections

    phase 3 small molecule completed

    1 trial

  12. EryDex Low dose DSP

    Quince Therapeutics

    Nervous System Disease

    phase 3 small molecule completed

    1 trial

  13. EryDex System

    Quince Therapeutics

    Ataxia Telangiectasia

    phase 3 other terminated

    1 trial

  14. Erythropoietin

    The First People's Hospital of Lianyungang

    Premature Infants

    phase 3 small molecule active

    1 trial

  15. Estradiol

    TherapeuticsMD

    Vulvovaginal Atrophy

    phase 3 small molecule completed

    1 trial

  16. Estradiol

    TherapeuticsMD

    Menopause

    phase 3 small molecule completed

    2 trials

  17. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  18. Eteplirsen

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 3 small molecule active

    2 trials

  19. Etoposide

    The First People's Hospital of Lianyungang

    Non-Hodgkin's Lymphoma

    phase 3 small molecule active

    1 trial

  20. Etoposide

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  21. Everolimus

    United Therapeutics Europe Ltd

    Pediatric Heart Transplantation

    phase 3 small molecule active

    1 trial

  22. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  23. Exoskeletal assisted walking

    United Therapeutics Europe Ltd

    Spinal Cord Injuries

    phase 3 other active

    1 trial

  24. Expressive Writing

    United Therapeutics Europe Ltd

    Posttraumatic Stress Disorder

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources